Methylation‑associated inactivation of JPH3 and its effect on prognosis and cell biological function in HCC

Huang,Yi; Yu,Zhou; Zheng,Min; Yang,Xiaohong; Huang,Honglan; Zhao,Lijin

doi:10.3892/mmr.2022.12640

Methylation‑associated inactivation of JPH3 and its effect on prognosis and cell biological function in HCC

Authors:
- Yi Huang
- Zhou Yu
- Min Zheng
- Xiaohong Yang
- Honglan Huang
- Lijin Zhao
View Affiliations

Affiliations: Department of Hepatobiliary Pancreatic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China
Published online on: February 14, 2022 https://doi.org/10.3892/mmr.2022.12640
Article Number: 124
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In recent years, researchers have found that epigenetics plays an important role in the occurrence and development of hepatocellular carcinoma (HCC). DNA methylation is involved in the proliferation and metastasis of HCC. However, the junctophilin 3 (JPH3) level and the potential regulatory mechanism of its DNA methylation in HCC remain uncertain. In the present study, 73 HCC samples were enrolled to analyze the expression of JPH3. Reverse‑transcription quantitative PCR, western blotting and immunohistochemistry were used to detect the expression of JPH3 in HCC. Kaplan‑Meier method and Cox regression analysis were applied to evaluate the prognostic impact of JPH3 on HCC patients. DNA methylation‑specific PCR and bisulfite Sanger sequencing were used to detect the degree of DNA methylation of JPH3 in HCC. The demethylation drug 5‑Aza‑2'‑deoxycytidine (5‑Aza) was used to reduce the DNA methylation of JPH3. The role of JPH3 in the malignant biological behavior of HCC by promoting epithelial‑mesenchymal transition (EMT) was confirmed by functional cell experiments. The results showed that JPH3 exhibited low levels in HCC tissues and cell lines. HCC patients with low expression of JPH3 had poor survival outcomes. JPH3 had higher DNA methylation levels in HCC tissues and cell lines. When the demethylation drug 5‑Aza was used to reduce the degree of methylation of JPH3, its protein expression level was significantly increased and it significantly inhibited the malignant biological behavior of HCC cells. Additionally, effective increase in the expression of JPH3 through gene regulation technology also inhibited the proliferation, invasion and migration of HCC cells. After altering the DNA methylation level of JPH3, the EMT of HCC cells was also affected. Therefore, our study demonstrated the inactivation of JPH3 by promoter methylation and its function as a tumor suppressor in HCC. JPH3 may serve as a biomarker for early diagnosis and as a potential therapeutic target for HCC.

View Figures

View References

1	Couri T and Pillai A: Goals and targets for personalized therapy for HCC. Hepatol Int. 13:125–137. 2019. View Article : Google Scholar : PubMed/NCBI
2	Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A and Roberts LR: A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 16:589–604. 2019. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Jiang J, Tang M, Huang Z and Chen L: Junctophilins emerge as novel therapeutic targets. J Cell Physiol. 234:16933–16943. 2019. View Article : Google Scholar : PubMed/NCBI
5	Margolis RL and Rudnicki DD: Pathogenic insights from Huntington's disease-like 2 and other Huntington's disease genocopies. Curr Opin Neurol. 29:743–748. 2016. View Article : Google Scholar : PubMed/NCBI
6	Hu X, Kuang Y, Li L, Tang H, Shi Q, Shu X, Zhang Y, Chan FK, Tao Q and He C: Epigenomic and functional characterization of junctophilin 3 (JPH3) as a novel tumor suppressor being frequently inactivated by promoter CpG methylation in digestive cancers. Theranostics. 7:2150–2163. 2017. View Article : Google Scholar : PubMed/NCBI
7	Han TS, Ban HS, Hur K and Cho HS: The epigenetic regulation of HCC metastasis. Int J Mol Sci. 19:39782018. View Article : Google Scholar : PubMed/NCBI
8	Dawson MA and Kouzarides T: Cancer epigenetics: From mechanism to therapy. Cell. 150:12–27. 2012. View Article : Google Scholar : PubMed/NCBI
9	Nebbioso A, Tambaro FP, Dell'Aversana C and Altucci L: Cancer epigenetics: Movin forward. PLoS Genet. 14:e10073622018. View Article : Google Scholar : PubMed/NCBI
10	Zhang L, Lu Q and Chang C: Epigenetics in health and disease. Adv Exp Med Biol. 1253:3–55. 2020. View Article : Google Scholar : PubMed/NCBI
11	Zhang D, Zhao J, Han C, Liu X, Liu J and Yang H: Identification of hub genes related to prognosis in glioma. Biosci Rep. 40:BSR201933772020. View Article : Google Scholar : PubMed/NCBI
12	Chen KH, He J, Wang DL, Cao JJ, Li MC, Zhao XM, Sheng X, Li WB and Liu WJ: Methylation-associated inactivation of LATS1 and its effect on demethylation or overexpression on YAP and cell biological function in human renal cell carcinoma. Int J Oncol. 45:2511–2521. 2014. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Huang A, Yang XR, Chung WY, Dennison AR and Zhou J: Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 5:1462020. View Article : Google Scholar : PubMed/NCBI
15	Jiang Y, Han QJ and Zhang J: Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol. 25:3151–3167. 2019. View Article : Google Scholar : PubMed/NCBI
16	Berger MF and Mardis ER: The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 15:353–365. 2018. View Article : Google Scholar : PubMed/NCBI
17	Zahn LM: Effects of the tumor microenvironment. Science. 355:1386–1388. 2017. View Article : Google Scholar
18	Villanueva A: Hepatocellular carcinoma. N Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
19	Xie DY, Ren ZG, Zhou J, Fan J and Gao Q: 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: Updates and insights. Hepatobiliary Surg Nutr. 9:452–463. 2020. View Article : Google Scholar : PubMed/NCBI
20	Ganne-Carrié N and Nahon P: Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 70:284–293. 2019. View Article : Google Scholar : PubMed/NCBI
21	Skvortsova K, Stirzaker C and Taberlay P: The DNA methylation landscape in cancer. Essays Biochem. 63:797–811. 2019. View Article : Google Scholar : PubMed/NCBI
22	Edwards JR, Yarychkivska O, Boulard M and Bestor TH: DNA methylation and DNA methyltransferases. Epigenetics Chromatin. 10:232017. View Article : Google Scholar : PubMed/NCBI
23	Lee J, Kim Y, Friso S and Choi SW: Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 54:78–88. 2017. View Article : Google Scholar : PubMed/NCBI
24	Pan Y, Liu G, Zhou F, Su B and Li Y: DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 18:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
25	Dor Y and Cedar H: Principles of DNA methylation and their implications for biology and medicine. Lancet. 392:777–786. 2018. View Article : Google Scholar : PubMed/NCBI
26	Toh TB, Lim JJ and Chow EK: Epigenetics of hepatocellular carcinoma. Clin Transl Med. 8:132019. View Article : Google Scholar : PubMed/NCBI
27	Raggi C and Invernizzi P: Methylation and liver cancer. Clin Res Hepatol Gastroenterol. 37:564–571. 2013. View Article : Google Scholar : PubMed/NCBI
28	Nakamura M, Chiba T, Kanayama K, Kanzaki H, Saito T, Kusakabe Y and Kato N: Epigenetic dysregulation in hepatocellular carcinoma: An up-to-date review. Hepatol Res. 49:3–13. 2019. View Article : Google Scholar : PubMed/NCBI
29	Maemura K, Yoshikawa H, Yokoyama K, Ueno T, Kurose H, Uchiyama K and Otsuki Y: Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma. Int J Oncol. 42:817–822. 2013. View Article : Google Scholar : PubMed/NCBI
30	Acun T, Oztas E, Yagci T and Yakicier MC: SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation. BMC Cancer. 11:2232011. View Article : Google Scholar : PubMed/NCBI
31	Pastushenko I and Blanpain C: EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
32	Saitoh M: Involvement of partial EMT in cancer progression. J Biochem. 164:257–264. 2018. View Article : Google Scholar : PubMed/NCBI
33	Aiello NM and Kang Y: Context-dependent EMT programs in cancer metastasis. J Exp Med. 216:1016–1026. 2019. View Article : Google Scholar : PubMed/NCBI
34	Guo F, Wang H, Jiang M, Yang Q, Xiang Q, Zhou H, Hu X, Hao K, Yang J, Cao H and Shen Z: TDP-43 induces EMT and promotes hepatocellular carcinoma metastasis via activating Wnt/β-catenin signaling pathway. Am J Cancer Res. 10:3285–3301. 2020.PubMed/NCBI
35	Lu J, Zhao Z and Ma Y: miR-186 represses proliferation, migration, invasion, and EMT of hepatocellular carcinoma via directly targeting CDK6. Oncol Res. 28:509–518. 2020. View Article : Google Scholar : PubMed/NCBI
36	Dian MJ, Li J, Zhang XL, Li ZJ, Zhou Y, Zhou W, Zhong QL, Pang WQ, Lin XL, Liu T, et al: MST4 negatively regulates the EMT, invasion and metastasis of HCC cells by inactivating PI3K/AKT/Snail1 axis. J Cancer. 12:4463–4477. 2021. View Article : Google Scholar : PubMed/NCBI